StoneX Group’s Cellyan Biotechnology HKPD Stock Holding History

StoneX Group’s Portfolio HKPD Stock Details HKPD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$33.9K	Buy	6,615 +1,499	+29%	+$9.41K	﹤0.01%	1663
2026 Q2	$52.4K	Buy	5,116 +3,146	+160%	+$34.4K	﹤0.01%	1222
2026 Q1	$22.4K	Sell	1,970 -194	-9%	-$2.82K	﹤0.01%	827
2025 Q4	$35.7K	Buy	+2,164	New	+$46.4K	﹤0.01%	947

StoneX Group's HKPD Position: Q3 2026 in Review

StoneX Group increased its Cellyan Biotechnology (HKPD) stake by 29% in Q3 2026, buying an estimated $9.41K and bringing the position to 6,615 shares worth $33.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1663.

StoneX Group first reported a position in HKPD in Q4 2025 and has held it in 4 quarters since. The position peaked at $52.4K in Q2 2026. 1 fund tracked by Wall St. Rank holds HKPD as of Q3 2026.

StoneX Group held 6,615 shares of Cellyan Biotechnology worth $33.9K as of Q3 2026.
StoneX Group bought 1,499 Cellyan Biotechnology shares in Q3 2026, an estimated $9.41K.
Cellyan Biotechnology made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1663 holding.
StoneX Group first reported a position in Cellyan Biotechnology in Q4 2025 and has held it in 4 quarters since.
StoneX Group's Cellyan Biotechnology position peaked at $52.4K in Q2 2026.
1 fund tracked by Wall St. Rank held Cellyan Biotechnology as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.